SOX2 and neoplasm: Furthermore, regarding reduced tumor volume, tumor weight, and elevated tumor apoptosis rate, it was worthy to note that OCT4&SOX2 CTLs plus PD-1 inhibitor (nivolumab) showed better effects compared to PD-1 inhibitor (nivolumab) alone and OCT4&SOX2 CTLs alone (Figures 4B–G).